この記事を読む

初回治療としてのニボルマブ+イピリムマブの使いどころはあるのか

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. Hellmann MD N Engl J Med. 2019 Sep 28.[Epub ahead of p…

この記事を読む

NEJ009 全生存期間の評価は?

Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor R…

この記事を読む

再発胸腺腫瘍にアムルビシンが有効

Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies. Hellyer JA et…

この記事を読む

悪性胸水への胸膜癒着術で予後改善?

Survival in patients with malignant pleural effusion undergoing talc pleurodesis. Hassan M et al. Lung Cancer. 2019 Sep …

この記事を読む

EGFR遺伝子変異サブタイプとICI治療

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer. Hastings K et…

この記事を読む

ラムシルマブ+エルロチニブ出番はあるか?

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a rand…

この記事を読む

PD-L1超高発現の生存データ:90%がカットオフ?

Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and very high PD-L1 expression. Aguilar…

この記事を読む

ニボルマブの4年生存率

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled anal…

この記事を読む

EGFR遺伝子変異は胸水検体だけで正しいか

Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with ade…

この記事を読む

終末期における胸部緩和照射

Palliative thoracic radiotherapy near the end of life in lung cancer: A population-based analysis. Fraser I et al. Lung …